<DOC>
	<DOC>NCT00975117</DOC>
	<brief_summary>The purpose of this study is to determine whether the administration of the dietary supplement Spermotrend improves spermatogenesis parameters in subjects with male infertility unrelated to major testicular conditions. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of males with infertility to be recruited and randomized for the study is 86.</brief_summary>
	<brief_title>Spermotrend in the Treatment of Male Infertility</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility, Male</mesh_term>
	<criteria>Male infertility unrelated to major testicular conditions Must have at least one altered seminal parameter. Signed informed consent Hydrocele, varicocele, orchitis, epididymitis, irradiation or Chemotherapy. Previously treated and cured testicular condition. Nontransmissible chronic diseases Use of antioxidant agents within 6 months. Use of vitamins within 6 months. Use of antiinflammatory drugs within 6 months. Use of hormones prescribed by an andrologist within 6 months Positive serology/HIV Leukocytospermia</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>male infertility</keyword>
	<keyword>spermatogenesis</keyword>
</DOC>